Mitsubishi Tanabe Pharma America Inc.

Dec 05, 2017

Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston

Nov 30, 2017

Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA® (edaravone) to U.S. Department of Veterans Affairs National Formulary

Nov 21, 2017

Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O'Brien as Vice President of Market Access

Nov 16, 2017

Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available

Sep 07, 2017

Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal

Sep 06, 2017

Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services

Aug 08, 2017

First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S.

Aug 01, 2017

MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America